Tiagabine: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Tiagabine. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Dizziness | 27% |
| Accidental injury | 21% |
| Asthenia | 20% |
| Infection | 19% |
| Somnolence | 18% |
| Difficulty with concentration/attention* | 14% |
| Nausea | 11% |
| Nervousness | 10% |
| Tremor | 9% |
| Flu syndrome | 9% |
| Amblyopia | 9% |
| Abdominal pain | 7% |
| Diarrhea | 7% |
| Vomiting | 7% |
| Pharyngitis | 7% |
| Pain | 7% |
| Concentration/attention* | 6% |
| Insomnia | 6% |
| Ecchymosis | 6% |
| Pain (unspecified) | 5% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Tiagabine HCl is indicated as adjunctive therapy in adults and children 12 years and older in the treatment of partial seizures.
Source: FDA labeling via NIH DailyMed (set 953ef3cc…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.